A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
for Systemic Sclerosis
17 locations incl. Scottsdale
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Sex: All·Age: 16+
Code: NCT07335562·Phase 3·Not Yet Recruiting·Listed Jan 2026